Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Cash & Equivalents (2012 - 2026)

Kamada's (KMDA) quarterly Cash & Equivalents came in at $29.5 million in Q2 2026, down 55.33% on a YoY basis from $66.0 million in Q2 2025, and down 10.48% quarter-over-quarter from $32.9 million in Q1 2026.

Analysis

Kamada (KMDA) Cash & Equivalents (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Cash & Equivalents for 15 consecutive years, with $29.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash & Equivalents fell 55.33% year-over-year to $29.5 million; the trailing twelve-month figure through Jun 2026 stood at $29.5 million (down 55.33% YoY), and the FY2025 full-year result was $75.5 million, down 3.78% from the prior year.
  • Cash & Equivalents eased to $29.5 million in Q2 2026 per KMDA's latest filing, from $32.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $78.4 million in Q4 2024 and bottomed at $29933.0 in Q2 2022.
  • Historically, Cash & Equivalents has averaged $47.3 million across 5 years, with a median of $50.4 million in 2023.
  • The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 99.96% in 2022, then jumped 72689.23% in 2023.
  • Over 5 years, Cash & Equivalents stood at $34.3 million in 2022, then soared by 62.42% to $55.6 million in 2023, then soared by 40.97% to $78.4 million in 2024, then declined by 3.78% to $75.5 million in 2025, then plunged by 60.95% to $29.5 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods registered $29.5 million, $32.9 million, and $75.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 13.99 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 3.18 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 6.14 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 2.46 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 3.58 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 1.72 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 1.71 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 1.29 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 1.25 Bn
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn 29.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 29.47 Mn
Mar 31, 2026 32.92 Mn
Dec 31, 2025 75.47 Mn
Sep 30, 2025 72.00 Mn
Jun 30, 2025 65.99 Mn
Mar 31, 2025 76.25 Mn
Dec 31, 2024 78.44 Mn
Sep 30, 2024 72.00 Mn
Jun 30, 2024 56.55 Mn
Mar 31, 2024 48.19 Mn
Dec 31, 2023 55.64 Mn
Sep 30, 2023 52.60 Mn
Jun 30, 2023 21.79 Mn
Mar 31, 2023 27.12 Mn
Dec 31, 2022 34.26 Mn
Sep 30, 2022 31.25 Mn
Jun 30, 2022 29,933.00
Mar 31, 2022 21.97 Mn
Dec 31, 2021 18.59 Mn
Sep 30, 2021 99.84 Mn